Core Viewpoint - Non-executive director Guo Huaqing increased his stake in Kexing Pharmaceutical-B (02171) by purchasing 30,000 shares at a price of HKD 16.4 per share, totaling HKD 492,000, which reflects confidence in the company's future prospects [1] Summary by Category - **Share Purchase Details** - Guo Huaqing acquired 30,000 shares at a price of HKD 16.4 each, amounting to a total investment of HKD 492,000 [1] - **Post-Purchase Holdings** - Following the purchase, Guo Huaqing's total shareholding in Kexing Pharmaceutical-B increased to approximately 218 million shares, representing a 37.73% ownership stake [1]

Core Viewpoint - Non-executive director Guo Huaqing increased his stake in Kintor Pharmaceutical (02171) by purchasing 30,000 shares at a price of HKD 16.4 per share, totaling HKD 492,000, which reflects confidence in the company's future prospects [1] Summary by Category - **Shareholding Activity** - Guo Huaqing's recent purchase brings his total shareholding to approximately 218 million shares, representing a 37.73% ownership stake in Kintor Pharmaceutical [1]

Core Insights - MSCI announced the results of its index review for November 2025, with adjustments effective after the market close on November 24 [1] - Kintor Pharmaceutical (stock code: 2171.HK) has been added to the MSCI Global Small Cap Index, transitioning from the MSCI Hong Kong Small Cap Index to the China region index [1] - Inclusion in MSCI indices is seen as a signal of recognition by global capital markets, potentially attracting passive fund allocations and enhancing liquidity for the company [1] Company Overview - Kintor Pharmaceutical is a leading player in the CGT (Cell and Gene Therapy) sector in China, focusing on innovative CAR-T cell therapies for treating hematological malignancies and solid tumors [1] - The company aims to address key challenges in the CAR-T field, including tackling hard-to-treat tumors and reducing treatment costs to make therapies more accessible to the public [1] - The inclusion in the MSCI Global Small Cap Index is expected to increase global investor attention on Kintor Pharmaceutical, further enhancing its stock liquidity and market valuation [1]

Summary of Key Points Core Viewpoint - On November 7, 43 Hong Kong-listed companies conducted share buybacks, totaling 24.24 million shares and an aggregate amount of HKD 163 million [1]. Group 1: Buyback Details - China Feihe repurchased 6 million shares for HKD 26.08 million, with a highest price of HKD 4.360 and a lowest price of HKD 4.340, bringing its total buyback amount for the year to HKD 310.46 million [1][2]. - COSCO Shipping Holdings repurchased 1.408 million shares for HKD 19.86 million, with a highest price of HKD 14.230 and a lowest price of HKD 13.800, accumulating a total buyback amount of HKD 4.678 billion for the year [1][2]. - Kintor Pharmaceutical repurchased 876,500 shares for HKD 13.78 million, with a highest price of HKD 16.000 and a lowest price of HKD 15.180, totaling HKD 47.76 million in buybacks for the year [1][2]. Group 2: Buyback Rankings - The highest buyback amount on November 7 was from China Feihe at HKD 26.08 million, followed by COSCO Shipping Holdings at HKD 19.86 million [1][2]. - In terms of share quantity, China Feihe led with 6 million shares repurchased, followed by China Petroleum & Chemical Corporation with 3.172 million shares and Linklogis Technology with 2.39 million shares [1][2]. Group 3: Additional Buyback Information - Other notable companies involved in buybacks include China Petroleum & Chemical Corporation, AAC Technologies, and Kintor Pharmaceutical, with respective buyback amounts of HKD 13.57 million, HKD 11.70 million, and HKD 7.49 million [2][3]. - The buyback activities reflect a trend among Hong Kong-listed companies to utilize excess cash for shareholder returns, indicating confidence in their financial health [1][2].

Group 1 - The core point of the article is that Kexing Pharmaceutical-B has been actively repurchasing its shares, indicating a potential confidence in its stock value and future performance [2][3] - On November 7, the company repurchased 876,500 shares at a price range of HKD 15.180 to HKD 16.000, totaling HKD 13.7793 million [2] - The stock closed at HKD 15.790 on the same day, reflecting a 0.70% increase, with a total trading volume of HKD 35.7076 million [2] Group 2 - Since November 6, the company has conducted share buybacks for two consecutive days, totaling 2.6105 million shares and an aggregate amount of HKD 40.0871 million [2] - The stock has experienced a cumulative increase of 1.02% during this buyback period [2] - Year-to-date, the company has completed four buyback transactions, repurchasing a total of 3.0655 million shares for a total amount of HKD 47.7551 million [3]

Core Viewpoint - 科济药业-B (02171.HK) announced a share buyback of 876,500 shares at a cost of HKD 13.78 million on November 7 [1] Group 1 - The company executed a buyback program, indicating confidence in its stock value [1] - The total expenditure for the buyback was HKD 13.78 million, reflecting a strategic move to enhance shareholder value [1] - The number of shares repurchased was 876,500, which may impact the company's share structure and market perception [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 科濟藥業控股有限公司 呈交日期： 2025年11月7日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02171 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | 佔有關 ...

Core Viewpoint - The non-executive director Guo Huaqing increased his stake in Kintor Pharmaceutical-B (02171) by purchasing 70,000 shares at a price of HKD 14.8 per share, totaling HKD 1.036 million, raising his total holdings to approximately 218 million shares, which represents a 37.72% ownership [1] Summary by Category - **Share Purchase Details** - Guo Huaqing acquired 70,000 shares of Kintor Pharmaceutical-B at HKD 14.8 each, amounting to HKD 1.036 million [1] - **Post-Purchase Holdings** - After the purchase, Guo's total shareholding in the company is about 218 million shares, equating to a 37.72% ownership stake [1]

Core Viewpoint - The non-executive director Guo Huaqing increased his stake in Kintor Pharmaceutical-B (02171) by purchasing 70,000 shares at a price of HKD 14.8 per share, totaling HKD 1.036 million, raising his total holdings to approximately 218 million shares, which represents 37.72% of the company [1] Summary by Category - **Share Purchase Details** - Guo Huaqing acquired 70,000 shares of Kintor Pharmaceutical-B at HKD 14.8 each [1] - The total investment amounted to HKD 1.036 million [1] - **Post-Purchase Holdings** - After the purchase, Guo Huaqing's total shareholding increased to approximately 218 million shares [1] - His ownership percentage in the company is now 37.72% [1]

Core Viewpoint - 科济药业 is actively repurchasing its shares to enhance shareholder value while continuing to develop innovative CAR-T therapies for unmet clinical needs [1][2] Group 1: Share Repurchase Activity - On November 6, 科济药业 announced the repurchase of 1.734 million shares at a price range of HKD 14.350 to HKD 15.8, totaling HKD 26.3078 million [1] - In the past month, the company has conducted three repurchase activities, acquiring a total of 2.189 million shares for a cumulative amount of HKD 33.9758 million [1] - The company has a repurchase plan allowing it to buy back up to 1% of its total issued shares in the open market [1] Group 2: Company Overview and Product Pipeline - 科济药业 is a biopharmaceutical company focused on developing innovative CAR-T cell therapies to address unmet clinical needs, including hematologic malignancies, solid tumors, and autoimmune diseases [1] - The company has 10 CAR-T pipeline products, including 4 autologous CAR-T and 6 universal CAR-T, all of which are self-developed with global rights [1] - The all-human BCMA autologous CAR-T product,赛恺泽, has been approved for marketing in China, while the Claudin18.2 autologous humanized CAR-T product,舒瑞基奥仑赛, is the first CAR-T product for solid tumors to submit a new drug application globally [1] Group 3: Recent R&D Achievements - On November 3, 科济药业 announced new clinical data for its universal CAR-T products, CT0596 and CT1190B, showing promising safety and efficacy signals for treating relapsed/refractory multiple myeloma and non-Hodgkin lymphoma, respectively [2] - As of June 30, 2026, the company reported cash and cash equivalents exceeding HKD 1.26 billion, indicating a strong financial position to support ongoing operations and share repurchase plans [2] - The management expressed commitment to maintaining the share repurchase program, adjusting it based on market conditions to further protect shareholder interests [2]